Which blazars are neutrino loud?

Protons accelerated in the cores of active galactic nuclei can effectively produce neutrinos only if the soft radiation background in the core is sufficiently high. We find restrictions on the spectral properties and luminosity of blazars under which they can be strong neutrino sources. We analyze the possibility that neutrino flux is highly beamed along the rotation axis of the central black hole. The enhancement of neutrino flux compared to GeV gamma-ray flux from a given source makes the detection of neutrino point sources more probable. At the same time the smaller open angle reduces the number of possible neutrino-loud blazars compared to the number of gamma-ray loud ones. We present the table of 15 blazars which are the most likely candidates for the detection by future neutrino telescopes.Comment: 9 pages, 5 figures, version to be published in PR

Gene variants associated with venous thrombosis: confirmation in the MEGA study

Thrombosis and Hemostasi

Semiautomated Clone Verification by Real-Time PCR Using Molecular Beacons

Conventional, high-throughput PCR analysis of common elements utilizing numerous primer sets and template DNA requires multiple rounds of PCR to ensure optimal conditions. Laborious gel electrophoresis and staining is then necessary to visualize amplification products. We propose novel multicolor molecular beacons, to establish a high-throughput, PCR-based sequence tagged site (STS) detection system that swiftly and accurately confirms marker content in template containing common repeat elements. A simple, one-tube, real-time PCR assay system was developed to specifically detect regions containing CA and GATA repeats. Ninetysix samples can be confirmed for marker content in a closed-tube format in 3 h, eliminating product confirmation on agarose gels and avoiding crossover contamination. Multiple STSs can be detected simultaneously in the same reaction tube by utilizing molecular beacons labeled with multicolor fluorophores. Template DNA from 260 RPCI-11 bacterial artificial chromosome (BAC) clones was examined for the presence of CA and/or GATA repeats using molecular beacon PCR and compared with conventional PCR results of the same clones. Of the 205 clones containing CA and GATA repeats, we were able to identify 129 clones (CA, n = 99; GATA, n = 30) by using molecular beacons and only 121 clones (CA, n = 92; GATA, n = 29) by conventional PCR amplification. As anticipated, 55 clones that contained sequences other than CA or GATA failed molecular beacon detection. Molecular beacon PCR, employing beacons specific for tandem repeat elements, provides a fast, accurate, and sensitive multiplex detection assay that will expedite verification of marker content in a multitude of template containing these repeats

KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study

<p><i>Background</i> Statin therapy has been found to substantially and significantly reduce coronary events in carriers of the KIF6 719Arg variant (rs20455) but not in noncarriers. We investigated whether, among the elderly, statin therapy also significantly reduced coronary events in carriers but not in noncarriers.</p> <p><i>Design and methods</i> Among 5752 patients of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study, we assessed the effect of pravastatin, compared with placebo, on coronary events according to 719Arg carrier status using proportional hazards models.</p> <p><i>Results</i> Since benefit from statin therapy in elderly patients has been primarily shown among those with prior vascular disease, we performed analyses in PROSPER patients with prior disease and found that pravastatin therapy significantly reduced events in 719Arg carriers [hazards ratio (HR): 0.66, 95% confidence interval (CI): 0.52–0.86] but not in noncarriers (HR: 0.94, 95% CI: 0.69–1.28), P= 0.09 for interaction between treatment and carrier status. Among those without prior disease, no significant benefit was observed in either carriers or noncarriers. Among those with prior vascular disease in the placebo arm, Trp719Arg heterozygotes were at significantly greater risk, compared with noncarriers (HR: 1.36, 95% CI: 1.03–1.81, P = 0.03); the HR of 719Arg carriers, compared with noncarriers, was 1.28 (95% CI: 0.98–1.69, P =0.07).</p> <p><i>Conclusion</i> Elderly carriers of the KIF6 719Arg variant with prior vascular disease received significant benefit from pravastatin therapy; no benefit was observed in noncarriers with prior disease or in those without prior disease (carriers or noncarriers).</p&gt

Schilbach-Rott syndrome in a third family: Further delineation of an autosomal dominant trait

We describe a father-son Mexican pair with typical features of Schilbach-Rott syndrome (SRS): ocular hypotelorism, cleft palate, hypospadias (only in the child), and microcephaly. This observation documents for the first time a male to male transmission and therefore confirms that the SRS is inherited as an autosomal dominant trait with variable expressivity

Schilbach-Rott syndrome in a third family: Further delineation of an autosomal dominant trait

We describe a father-son Mexican pair with typical features of Schilbach-Rott syndrome (SRS): ocular hypotelorism, cleft palate, hypospadias (only in the child), and microcephaly. This observation documents for the first time a male to male transmission and therefore confirms that the SRS is inherited as an autosomal dominant trait with variable expressivity